Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) FCF Margin (2016 - 2025)

Fate Therapeutics' FCF Margin history spans 14 years, with the latest figure at 2108.77% for Q4 2025.

  • For Q4 2025, FCF Margin fell 57581.0% year-over-year to 2108.77%; the TTM value through Dec 2025 reached 1685.78%, down 77899.0%, while the annual FY2025 figure was 1685.78%, 77899.0% down from the prior year.
  • FCF Margin reached 2108.77% in Q4 2025 per FATE's latest filing, down from 1275.93% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 54.37% in Q1 2023 to a low of 3289.6% in Q2 2023.
  • Average FCF Margin over 5 years is 1060.92%, with a median of 715.98% recorded in 2024.
  • Peak YoY movement for FCF Margin: tumbled -304946bps in 2023, then soared 281073bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 247.99% in 2021, then grew by 1bps to 245.66% in 2022, then tumbled by -645bps to 1829.65% in 2023, then grew by 16bps to 1532.96% in 2024, then crashed by -38bps to 2108.77% in 2025.
  • Per Business Quant, the three most recent readings for FATE's FCF Margin are 2108.77% (Q4 2025), 1275.93% (Q3 2025), and 1389.09% (Q2 2025).